epstein-barr

HLA-A*0301-restricted epitope from Epstein-Barr Virus , EBV BRLF-1 (148-156).

CEF27, Epstein-Barr Virus BRLF-1 lytic 148-156 acetate corresponding to amino acids 148-156 of the BRLF1. BRLF1 is a transcriptional activator that binds directly to a GC-rich motif present in some Epstein-Barr virus (EBV) lytic gene promoters.

CEF19, Epstein-Barr Virus latent NA-3A (458-466), is a peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain).

CEF14, EBV Rta Protein (28-37), is the HLA A24-restricted epitope from the Epstein-Barr virus Rta Protein (28-37).

CEF6, a HLA-B7 restricted influenza virus nucleoprotein epitope, belongs to the CEF control peptides. The CEF control peptides are 8-12 amino acids in length, with sequences derived from the human cytomegalovirus, Epstein-Barr virus and influenza virus.

CEF6 acetate is a HLA-B7 restricted influenza virus nucleoprotein epitope, belongs to the CEF control peptides. The CEF control peptides are 8-12 amino acids in length, with sequences derived from the human cytomegalovirus, Epstein-Barr virus and influenz

EBVBZLF1 (190-197) TFA is an immunodominant CEF control peptide derived from the Epstein-Barr virus (EBV). It serves as an optimal epitope for CD8+ T cells, facilitating the release of IFNg. The CD8 positive cytotoxic T lymphocyte (CTL) response elicited by EBVBZLF1 (190-197) TFA is diverse and capable of cross-recognizing similar peptide segments from both host proteins and bacterial proteins. This compound is useful for research in autoimmune diseases.